Cargando…

Evaluation of non-alcoholic fatty liver disease in patients with inflammatory bowel disease using controlled attenuation parameter technology: A Taiwanese retrospective cohort study

BACKGROUND/PURPOSE: An increased prevalence of non-alcoholic fatty liver disease (NAFLD) is observed in patients with inflammatory bowel disease (IBD) in Western countries. Both intestinal inflammation and metabolic factors contribute to the pathogenesis of IBD-associated NAFLD. The burden of NAFLD...

Descripción completa

Detalles Bibliográficos
Autores principales: Yen, Hsu-Heng, Su, Pei-Yuan, Huang, Siou-Ping, Wu, Lisha, Hsu, Tsui-Chun, Zeng, Ya-Huei, Chen, Yang-Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8158967/
https://www.ncbi.nlm.nih.gov/pubmed/34043691
http://dx.doi.org/10.1371/journal.pone.0252286
_version_ 1783699980723159040
author Yen, Hsu-Heng
Su, Pei-Yuan
Huang, Siou-Ping
Wu, Lisha
Hsu, Tsui-Chun
Zeng, Ya-Huei
Chen, Yang-Yuan
author_facet Yen, Hsu-Heng
Su, Pei-Yuan
Huang, Siou-Ping
Wu, Lisha
Hsu, Tsui-Chun
Zeng, Ya-Huei
Chen, Yang-Yuan
author_sort Yen, Hsu-Heng
collection PubMed
description BACKGROUND/PURPOSE: An increased prevalence of non-alcoholic fatty liver disease (NAFLD) is observed in patients with inflammatory bowel disease (IBD) in Western countries. Both intestinal inflammation and metabolic factors contribute to the pathogenesis of IBD-associated NAFLD. The burden of NAFLD is not clear in the Asian population. This study aimed to evaluate the prevalence of NAFLD and liver fibrosis in a cohort of Taiwanese patients with IBD. METHODS: From January to December 2019, patients with IBD who underwent ultrasound examination were enrolled. Hepatic steatosis and fibrosis were measured with liver stiffness measurement (LSM) and controlled attenuation parameter (CAP) using FibroScan. Patients with a history of excessive alcohol or recent steroid use were excluded. Univariate and multivariate analysis were performed. RESULTS: A total of 81 consecutive patients were enrolled and included in the analysis (45 with ulcerative colitis, 36 with Crohn’s disease). The median age was 42 years old. The patients were classified in terms of body mass index as normal weight (54.3%), underweight (11.1%), overweight (28.4%), and obese (6.2%). The mean CAP increased to 162.22 dB/m in the underweight group, 210.86 dB/m in the normal weight group, 260.7 dB/m in the overweight group, and 274.0 dB/m in the obese group. NAFLD was observed in 29.6% of the patients, 1.2% of which had significant fibrosis. Increased body mass index (odds ratio [OR] 1.33, 95% confidence interval [CI] 1.1–1.62) and older age at IBD diagnosis (OR: 1.05, 95% CI 1–1.11) was found to be associated with the presence of NAFLD. CONCLUSION: In this study, the prevalence of NAFLD was lower (29.6%) in IBD patients than in the Western population. Higher BMI and older age were associated with NAFLD in our study.
format Online
Article
Text
id pubmed-8158967
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-81589672021-06-09 Evaluation of non-alcoholic fatty liver disease in patients with inflammatory bowel disease using controlled attenuation parameter technology: A Taiwanese retrospective cohort study Yen, Hsu-Heng Su, Pei-Yuan Huang, Siou-Ping Wu, Lisha Hsu, Tsui-Chun Zeng, Ya-Huei Chen, Yang-Yuan PLoS One Research Article BACKGROUND/PURPOSE: An increased prevalence of non-alcoholic fatty liver disease (NAFLD) is observed in patients with inflammatory bowel disease (IBD) in Western countries. Both intestinal inflammation and metabolic factors contribute to the pathogenesis of IBD-associated NAFLD. The burden of NAFLD is not clear in the Asian population. This study aimed to evaluate the prevalence of NAFLD and liver fibrosis in a cohort of Taiwanese patients with IBD. METHODS: From January to December 2019, patients with IBD who underwent ultrasound examination were enrolled. Hepatic steatosis and fibrosis were measured with liver stiffness measurement (LSM) and controlled attenuation parameter (CAP) using FibroScan. Patients with a history of excessive alcohol or recent steroid use were excluded. Univariate and multivariate analysis were performed. RESULTS: A total of 81 consecutive patients were enrolled and included in the analysis (45 with ulcerative colitis, 36 with Crohn’s disease). The median age was 42 years old. The patients were classified in terms of body mass index as normal weight (54.3%), underweight (11.1%), overweight (28.4%), and obese (6.2%). The mean CAP increased to 162.22 dB/m in the underweight group, 210.86 dB/m in the normal weight group, 260.7 dB/m in the overweight group, and 274.0 dB/m in the obese group. NAFLD was observed in 29.6% of the patients, 1.2% of which had significant fibrosis. Increased body mass index (odds ratio [OR] 1.33, 95% confidence interval [CI] 1.1–1.62) and older age at IBD diagnosis (OR: 1.05, 95% CI 1–1.11) was found to be associated with the presence of NAFLD. CONCLUSION: In this study, the prevalence of NAFLD was lower (29.6%) in IBD patients than in the Western population. Higher BMI and older age were associated with NAFLD in our study. Public Library of Science 2021-05-27 /pmc/articles/PMC8158967/ /pubmed/34043691 http://dx.doi.org/10.1371/journal.pone.0252286 Text en © 2021 Yen et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Yen, Hsu-Heng
Su, Pei-Yuan
Huang, Siou-Ping
Wu, Lisha
Hsu, Tsui-Chun
Zeng, Ya-Huei
Chen, Yang-Yuan
Evaluation of non-alcoholic fatty liver disease in patients with inflammatory bowel disease using controlled attenuation parameter technology: A Taiwanese retrospective cohort study
title Evaluation of non-alcoholic fatty liver disease in patients with inflammatory bowel disease using controlled attenuation parameter technology: A Taiwanese retrospective cohort study
title_full Evaluation of non-alcoholic fatty liver disease in patients with inflammatory bowel disease using controlled attenuation parameter technology: A Taiwanese retrospective cohort study
title_fullStr Evaluation of non-alcoholic fatty liver disease in patients with inflammatory bowel disease using controlled attenuation parameter technology: A Taiwanese retrospective cohort study
title_full_unstemmed Evaluation of non-alcoholic fatty liver disease in patients with inflammatory bowel disease using controlled attenuation parameter technology: A Taiwanese retrospective cohort study
title_short Evaluation of non-alcoholic fatty liver disease in patients with inflammatory bowel disease using controlled attenuation parameter technology: A Taiwanese retrospective cohort study
title_sort evaluation of non-alcoholic fatty liver disease in patients with inflammatory bowel disease using controlled attenuation parameter technology: a taiwanese retrospective cohort study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8158967/
https://www.ncbi.nlm.nih.gov/pubmed/34043691
http://dx.doi.org/10.1371/journal.pone.0252286
work_keys_str_mv AT yenhsuheng evaluationofnonalcoholicfattyliverdiseaseinpatientswithinflammatoryboweldiseaseusingcontrolledattenuationparametertechnologyataiwaneseretrospectivecohortstudy
AT supeiyuan evaluationofnonalcoholicfattyliverdiseaseinpatientswithinflammatoryboweldiseaseusingcontrolledattenuationparametertechnologyataiwaneseretrospectivecohortstudy
AT huangsiouping evaluationofnonalcoholicfattyliverdiseaseinpatientswithinflammatoryboweldiseaseusingcontrolledattenuationparametertechnologyataiwaneseretrospectivecohortstudy
AT wulisha evaluationofnonalcoholicfattyliverdiseaseinpatientswithinflammatoryboweldiseaseusingcontrolledattenuationparametertechnologyataiwaneseretrospectivecohortstudy
AT hsutsuichun evaluationofnonalcoholicfattyliverdiseaseinpatientswithinflammatoryboweldiseaseusingcontrolledattenuationparametertechnologyataiwaneseretrospectivecohortstudy
AT zengyahuei evaluationofnonalcoholicfattyliverdiseaseinpatientswithinflammatoryboweldiseaseusingcontrolledattenuationparametertechnologyataiwaneseretrospectivecohortstudy
AT chenyangyuan evaluationofnonalcoholicfattyliverdiseaseinpatientswithinflammatoryboweldiseaseusingcontrolledattenuationparametertechnologyataiwaneseretrospectivecohortstudy